Added to YB: 2026-03-18
Pitch date: 2026-03-16
ALLO [neutral]
Allogene Therapeutics, Inc.
-7.35%
current return
Author Info
No bio for this author
Company Info
Allogene Therapeutics, Inc. a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer and autoimmune diseases.
Market Cap
$585.1M
Pitch Price
$2.45
Price Target
N/A
Dividend
N/A
EV/EBITDA
-2.29
P/E
-2.77
EV/Sales
N/A
Sector
Biotechnology
Category
special_situation
BIOTECH MARKET RESEARCH $ALLO | Ep. 960
ALLO (quick overview): ALPHA3 futility MRD analysis for cema-cel (ALLO-501A) in first-line LBCL expected early Q2 2026. Stock re-rates if MRD-negative conversion rates show ~25-30% absolute improvement vs control arm. Investors weigh MRD clearance delta, durability, safety (CRS/neurotoxicity), & feasibility post-frontline. Options price ±125% volatility on binary outcome.
Read full article (2 min)